EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands

Felix E de Jongh, Reva Efe, Kirsten H Herrmann, Jelle A Spoorendonk iD

International Journal of Breast Cancer · 22.09.2022 · 2022 · 1-12

DOI: 10.1155/2022/5909724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Breast Cancer, erschienen am 22.09.2022. Verfasst von Felix E de Jongh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Center South Holland South, Ikazia Ziekenhuis Rotterdam, Montessoriweg 1, 3083 AN, Rotterdam, Netherlands. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exact Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant chemotherapy, genomic profile testing performed with tests such as the Oncotype DX® test can help healthcare practitioners decide whether chemotherapy provides any benefit to these patients. As such, a cost-consequence model was developed with the aim to estimate the economic impact of using different gene expression tests or no testing, in patients with node-negative early-stage breast cancer.

Methods

A cost-consequence model was developed to estimate the economic impact of three different scenarios in the Dutch setting: (1) Oncotype DX® test, (2) MammaPrint®, and (3) and no genomic profile testing. The model included chemotherapy costs, administration costs, short- and long-term adverse event costs, productivity loss, genomic profiling testing costs, cost of cancer recurrence, and hospitalization costs.

Results

A treatment paradigm with Oncotype DX resulted in average savings per patient of €6,768 vs. a paradigm with MammaPrint and €13,125 vs. a paradigm with no genomic testing. Furthermore, due to less patients receiving adjuvant chemotherapy through better targeting by the Oncotype DX test, fewer adverse events, sick days, practice visits, and hospitalizations were required compared to MammaPrint and no genomic profiling.

Conclusions

Testing with Oncotype DX test in Dutch clinical practice in patients with early-stage breast cancer proved to be cost-saving versus MammaPrint and no genomic profiling tests. Introducing the Oncotype DX test to the Dutch setting will likely reduce the economic resources that are required.

Autor:innen und Institutionen

  • Breast Cancer Center South Holland South, Ikazia Ziekenhuis Rotterdam, Montessoriweg 1, 3083 AN, Rotterdam, Netherlands.
  • OPEN Health, Marten Meesweg 107, 3068 AV, Rotterdam, Netherlands.
  • Exact Sciences Deutschland GmbH, 51103 Cologne, Erna-Scheffler-Str. 1a, Germany.

ORCID-Profile: Jelle A Spoorendonk

Förderung

  • Exact Sciences

Zitieren

APA

de Jongh, F. E., Efe, R., Herrmann, K. H., & Spoorendonk, J. A. (2022). Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. International Journal of Breast Cancer, 2022, 1-12. https://doi.org/10.1155/2022/5909724

Vancouver

de Jongh FE, Efe R, Herrmann KH, Spoorendonk JA. Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. International Journal of Breast Cancer. 2022;2022:1-12. doi:10.1155/2022/5909724

BibTeX
@article{deJongh2022,
  author = {de Jongh, Felix E and Efe, Reva and Herrmann, Kirsten H and Spoorendonk, Jelle A},
  title = {Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands},
  journal = {International Journal of Breast Cancer},
  year = {2022},
  volume = {2022},
  pages = {1--12},
  doi = {10.1155/2022/5909724}
}
Kostenlos starten →